Abstract
Cancer Oncolytic viruses can selectively infect cancer cells to stimulate cell death and antiviral and antitumor immune responses. Fares et al. report a phase 1 trial in patients with high-grade glioma treated with an engineered oncolytic adenovirus delivered by neural stem cells (NSCs). Delivery of oncolytic viruses in NSCs has been previously shown in mouse models to improve the delivery and distribution of virus particles within gliomas. The 12 patients underwent surgical resection, and the NSCs containing oncolytic virus were injected into the brain. The patients were then treated with chemotherapy plus radiotherapy. The trial showed that the NSC-oncolytic virus treatment was safe, and there was some evidence of immune stimulation and potential survival benefit, although this was not a placebo-controlled study. Lancet Oncol. 10.1016/S1470-2045(21)00245-X (2021).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
